{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:07:12Z","timestamp":1794017232250,"version":"4.8.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017239","name":"BeOne Medicines Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017239","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009108","name":"Shandong University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.eclinm.2025.103709","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T07:10:39Z","timestamp":1765869039000},"page":"103709","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Neoadjuvant tislelizumab plus nab-paclitaxel and carboplatin for triple-negative breast cancer: a multicenter, open-label, phase II cTRIO study"],"prefix":"10.1016","volume":"91","author":[{"given":"Fei","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaopeng","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuizhi","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenzhen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peifen","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zefei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2025.103709_bib1","first-page":"477","article-title":"Breast cancer statistics 2024","volume":"74","author":"Giaquinto","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.eclinm.2025.103709_bib2","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1146\/annurev-pathol-042420-093238","article-title":"Pathogenesis of triple-negative breast cancer","volume":"17","author":"Derakhshan","year":"2022","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.eclinm.2025.103709_bib3","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41523-022-00468-0","article-title":"Triple negative breast cancer: pitfalls and progress","volume":"8","author":"Zagami","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.eclinm.2025.103709_bib4","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1053\/j.seminoncol.2020.05.006","article-title":"Early stage triple negative breast cancer: management and future directions","volume":"47","author":"Chaudhary","year":"2020","journal-title":"Semin Oncol"},{"key":"10.1016\/j.eclinm.2025.103709_bib5","first-page":"106","article-title":"Current approaches in treatment of triple-negative breast cancer","volume":"12","author":"Wahba","year":"2015","journal-title":"Cancer Biol Med"},{"key":"10.1016\/j.eclinm.2025.103709_bib6","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s12916-019-1326-5","article-title":"Recent advances in triple negative breast cancer: the immunotherapy era","volume":"17","author":"Marra","year":"2019","journal-title":"BMC Med"},{"key":"10.1016\/j.eclinm.2025.103709_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108111","article-title":"The immune modifying effects of chemotherapy and advances in chemo-immunotherapy","volume":"236","author":"Principe","year":"2022","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.eclinm.2025.103709_bib8","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2025.103709_bib9","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(20)31953-X","volume":"396","author":"Mittendorf","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2025.103709_bib10","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMoa2112651","article-title":"Event-free survival with pembrolizumab in early triple-negative breast cancer","volume":"386","author":"Schmid","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2025.103709_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.10.008","article-title":"Pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage TNBC: updated EFS results from the phase III KEYNOTE-522 study","volume":"34","author":"Schmid","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eclinm.2025.103709_bib12","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.2217\/fon-2021-1647","article-title":"KEYNOTE-522, IMpassion031 and GeparNUEVO: changing the paradigm of neoadjuvant immune checkpoint inhibitors in early triple-negative breast cancer","volume":"18","author":"Rizzo","year":"2022","journal-title":"Future Oncol"},{"key":"10.1016\/j.eclinm.2025.103709_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.09.460","article-title":"Efficacy and safety of neoadjuvant chemotherapy combination with pembrolizumab in triple-negative breast cancer: Real-world data","volume":"34","author":"Rached","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eclinm.2025.103709_bib14","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41523-022-00386-1","article-title":"Immunotherapy for early triple negative breast cancer: research agenda for the next decade","volume":"8","author":"Tarantino","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.eclinm.2025.103709_bib15","doi-asserted-by":"crossref","first-page":"S1241","DOI":"10.1016\/j.annonc.2020.10.021","article-title":"KEYNOTE-522 Asian subgroup: phase III study of neoadjuvant pembrolizumab (pembro) vs placebo (pbo) + chemotherapy (chemo) followed by adjuvant pembro vs pbo for early triple-negative breast cancer (TNBC)","volume":"31","author":"Dent","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eclinm.2025.103709_bib16","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1001\/jamaoncol.2023.5033","article-title":"Clinical and biomarker findings of neoadjuvant pembrolizumab and carboplatin plus docetaxel in triple-negative breast cancer: NeoPACT phase 2 clinical trial","volume":"10","author":"Sharma","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eclinm.2025.103709_bib17","doi-asserted-by":"crossref","first-page":"60647","DOI":"10.18632\/oncotarget.10607","article-title":"Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.eclinm.2025.103709_bib18","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s00262-018-2160-x","article-title":"The binding of an anti-PD-1 antibody to Fc\u03b3R\u0399 has a profound impact on its biological functions","volume":"67","author":"Zhang","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.eclinm.2025.103709_bib19","doi-asserted-by":"crossref","DOI":"10.1177\/10732748221111296","article-title":"Tislelizumab: a modified anti-tumor programmed death receptor 1 antibody","volume":"29","author":"Zhang","year":"2022","journal-title":"Cancer Control"},{"key":"10.1016\/j.eclinm.2025.103709_bib21","doi-asserted-by":"crossref","first-page":"6","DOI":"10.21037\/tbcr-23-4","article-title":"Prospect of neoadjuvant\/adjuvant immunotherapy in early-stage triple-negative breast cancer","volume":"4","author":"Hao","year":"2023","journal-title":"Transl Breast Cancer Res"},{"key":"10.1016\/j.eclinm.2025.103709_bib22","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline focused update","volume":"36","author":"Wolff","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2025.103709_bib23","article-title":"AdvanTIG-202: a phase 2 study investigating anti-TIGIT monoclonal antibody ociperlimab plus anti-PD-1 monoclonal antibody tislelizumab in patients with previously treated recurrent or metastatic cervical cancer","volume":"39","author":"Wu","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2025.103709_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.eclinm.2025.103709_bib25","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1093\/jnci\/djx258","article-title":"Comparison of neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in triple-negative breast cancer: randomized WSG-ADAPT-TN trial results","volume":"110","author":"Gluz","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eclinm.2025.103709_bib26","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41591-019-0432-4","article-title":"Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial","volume":"25","author":"Voorwerk","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.eclinm.2025.103709_bib27","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","article-title":"Overall survival with pembrolizumab in early-stage triple-negative breast cancer","volume":"391","author":"Schmid","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2025.103709_bib28","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1093\/oncolo\/oyae064","article-title":"Impact of neoadjuvant pembrolizumab adherence on pathologic complete response in triple-negative breast cancer: a real-world analysis","volume":"29","author":"LeVee","year":"2024","journal-title":"Oncologist"},{"key":"10.1016\/j.eclinm.2025.103709_bib29","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1158\/1078-0432.CCR-20-3646","article-title":"Randomized phase II trial of anthracycline-free and anthracycline-containing neoadjuvant carboplatin chemotherapy regimens in stage I-III triple-negative breast cancer (NeoSTOP)","volume":"27","author":"Sharma","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eclinm.2025.103709_bib30","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1002\/ijc.33830","article-title":"Neoadjuvant docetaxel plus carboplatin vs epirubicin plus cyclophosphamide followed by docetaxel in triple-negative, early-stage breast cancer (NeoCART): results from a multicenter, randomized controlled, open-label phase II trial","volume":"150","author":"Zhang","year":"2022","journal-title":"Int J Cancer"},{"key":"10.1016\/j.eclinm.2025.103709_bib31","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1001\/jamaoncol.2020.2965","article-title":"Effect of adjuvant paclitaxel and carboplatin on survival in women with triple-negative breast cancer: a phase 3 randomized clinical trial","volume":"6","author":"Yu","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eclinm.2025.103709_bib32","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1007\/s12672-025-03435-w","article-title":"Efficacy and safety of platinum-based, anthracycline-free neoadjuvant chemotherapy for triple-negative breast cancer: a systematic review and meta-analysis","volume":"16","author":"Du","year":"2025","journal-title":"Discov Oncol"},{"key":"10.1016\/j.eclinm.2025.103709_bib33","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S1470-2045(15)00542-2","article-title":"Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial","volume":"17","author":"Untch","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eclinm.2025.103709_bib34","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.annonc.2022.02.004","article-title":"Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study","volume":"33","author":"Gianni","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eclinm.2025.103709_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2024.102171","article-title":"Comparative efficacy of anthracycline-free and anthracycline-containing neoadjuvant chemoimmunotherapy regimens for triple-negative breast cancer","volume":"51","author":"Wei","year":"2025","journal-title":"Transl Oncol"},{"key":"10.1016\/j.eclinm.2025.103709_bib36","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1186\/s12916-024-03474-0","article-title":"Taxane combined with lobaplatin or anthracycline for neoadjuvant chemotherapy of triple-negative breast cancer: a randomized, controlled, phase II study","volume":"22","author":"Wang","year":"2024","journal-title":"BMC Med"},{"key":"10.1016\/j.eclinm.2025.103709_bib37","article-title":"Lobaplatin-based neoadjuvant chemotherapy for triple-negative breast cancer: a 5-year follow-up of a randomized, open-label, phase II trial","volume":"14","author":"Yan","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.eclinm.2025.103709_bib38","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.annonc.2022.07.1940","article-title":"Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response","volume":"33","author":"Loibl","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eclinm.2025.103709_bib39","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1200\/JCO.2010.32.1877","article-title":"Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer","volume":"29","author":"Hernandez-Aya","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2025.103709_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1019925","article-title":"Clinical N3 is an independent risk factor of recurrence for breast cancer patients achieving pathological complete response and near-pathological complete response after neoadjuvant chemotherapy","volume":"12","author":"Qian","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.eclinm.2025.103709_bib41","doi-asserted-by":"crossref","first-page":"18","DOI":"10.21037\/tbcr-24-31","article-title":"Chinese Society of Clinical Oncology (CSCO) Breast Cancer guidelines 2024","volume":"5","author":"Li","year":"2024","journal-title":"Transl Breast Cancer Res"},{"key":"10.1016\/j.eclinm.2025.103709_bib42","doi-asserted-by":"crossref","first-page":"331","DOI":"10.6004\/jnccn.2024.0035","article-title":"Breast cancer, version 3.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Gradishar","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.eclinm.2025.103709_bib43","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.974376","article-title":"PD-1 inhibitor-based adverse events in solid tumors: a retrospective real-world study","volume":"13","author":"Huang","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.eclinm.2025.103709_bib44","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1093\/jnci\/djab121","article-title":"Determining PD-L1 status in patients with triple-negative breast cancer: lessons learned from IMpassion130","volume":"114","author":"Badve","year":"2022","journal-title":"J Natl Cancer Inst"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025006431?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025006431?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T11:24:19Z","timestamp":1777634659000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537025006431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":43,"alternative-id":["S2589537025006431"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103709","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neoadjuvant tislelizumab plus nab-paclitaxel and carboplatin for triple-negative breast cancer: a multicenter, open-label, phase II cTRIO study","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103709","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103709"}}